iuvo BioScience acquires Promedica International
Click Here to Manage Email Alerts
Key takeaways:
- iuvo BioScience acquired Promedica International.
- Shannon Stoddard was appointed as president of clinical research.
In an effort to expand its ophthalmic clinical research services, iuvo BioScience has acquired Promedica International, according to a press release.
With the acquisition, iuvo appointed Promedica International (PMI) president and owner Shannon Stoddard as its president of clinical research. Stoddard will also serve on the board of directors at iuvo.
“Shannon’s employee-centric and sponsor-dedicated approach is a perfect strategic and cultural fit with the iuvo team,” Ben Burton, iuvo president and CEO, said in the release. “Under Shannon’s leadership, we will remain focused on what has made each business successful: excellent client service, outstanding therapeutic expertise and an experienced team dedicated to collaborating with each other and the sponsor.”
With the backing of Ampersand Capital Partners, iuvo said it is positioned to grow as a global leader in laboratory, consulting and clinical development services with a focus on ophthalmology and the broader medical device market.
“The PMI team is thrilled to join iuvo BioScience,” Stoddard said in the release. “Our company was formed nearly 40 years ago with the sole focus of providing differentiated clinical research services to medical device and pharmaceutical companies across the globe. We have had an impressive track record of sponsor approvals and look forward to continuing this trend as part of iuvo.”
Read more about
Click Here to Manage Email Alerts